UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
Stocks · News reference
Pacific Biosciences Of California Approves Restructuring Plan To Align With Strategic Initiatives; Restructuring To Reduce Workforce By About 8%; Expects $30M-$40M Annualized Operating Expense Reduction By End Of 2027; Estimates $2M Pre-Tax Charges For Reduction In Force
On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuring plan to continue to better align the Company’s organizational structure and resources with its strategic
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine
Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.